Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immunome (IMNM) Other Operating Expenses (2023 - 2024)

Historic Other Operating Expenses for Immunome (IMNM) over the last 2 years, with Q4 2024 value amounting to $27.4 million.

  • Immunome's Other Operating Expenses fell 6612.46% to $27.4 million in Q4 2024 from the same period last year, while for Sep 2025 it was $27.4 million, marking a year-over-year decrease of 8669.8%. This contributed to the annual value of $152.3 million for FY2024, which is 8853.99% up from last year.
  • Latest data reveals that Immunome reported Other Operating Expenses of $27.4 million as of Q4 2024, which was down 6612.46% from $6.7 million recorded in Q3 2024.
  • Immunome's Other Operating Expenses' 5-year high stood at $112.0 million during Q1 2024, with a 5-year trough of $6.3 million in Q2 2024.